Bortecad 2.5mg Injection

Bortecad 2.5mg Injection is a chemotherapy drug, specifically a proteasome inhibitor which is used in the treatment of multiple myeloma mantle cell lymphoma. It works by killing cancer cells by disrupting protein breakdown. Medicine active ingredient is Bortezomib Injection IP. This medication should be administered under the supervision of an oncologist and the exact dosage and schedule is determined based on the patient's condition and response to the treatment.

Multiple myeloma, mantle cell lymphoma

Every medicine has several side effects, Bortecad 2.5mg Injection has also some side effects. Some of them resolve on their own and some need proper medical attention. Consult the doctor if the symptoms persist:
● High blood pressure
● Breathlessness
● Fungal infection
● Anemia
● Itching
● Pneumonia
● Dry skin
● Gastronintestinal bleeding
● Dehydration
● Motor neuropathy

Bortecad 2.5mg Injection should be taken at once everyday to better efficacy. You should take it exactly as the doctor recommends, do not skip or stop the medicine as this may reduce treatment effectiveness and allow cancer cells to grow. Follow the oncologist instructions carefully regarding dosage, timings and treatment cycles.

Bortecad 2.5mg Injection is an anti-cancer medication. Doctor use this as a first line therapy as it blocks the protein which is responsible in the growth of cancer cells and provides targeted action against malignant cells, helping to reduce tumor growth while minimizing damage to healthy cells.

• Duggett, N. A., & Flatters, S. J. (2017). Characterization of a rat model of bortezomib‐induced painful neuropathy. British journal of pharmacology, 174(24), 4812-4825.
• Wang, W., Cho, H. Y., Rosenstein-Sisson, R., Ramos, N. I. M., Price, R., Hurth, K., ... & Chen, T. C. (2017). Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model. Journal of neurosurgery, 128(3), 695-700.
• Bross, P. F., Kane, R., Farrell, A. T., Abraham, S., Benson, K., Brower, M. E., ... & Pazdur, R. (2004). Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clinical cancer research, 10(12), 3954-3964.
• Zhu, Q., Lin, X., Liu, X., Hou, T., Zhang, M., Wang, N., ... & Xiao, W. (2018). Dynamic changes of proteasome and protective effect of bortezomib, a proteasome inhibitor, in mice with acute pancreatitis. Biochemical and Biophysical Research Communications, 505(1), 126-133.
• Li, C., Deng, T., Shang, Z., Wang, D., & Xiao, Y. (2018). Blocking TRPA1 and TNF-α signal improves bortezomib-induced neuropathic pain. Cellular Physiology and Biochemistry, 51(5), 2098-2110.